title: Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.
abstract: While the majority of children and adolescents with newly diagnosed childhood acute lymphoblastic leukemia (ALL) will be cured, as many as 20 % of patients will experience relapse. On current treatment regimens, the intensity of upfront treatment is stratified based upon prognostic factors with the aim of improving cure rates (for those at the highest risk of relapse) and minimizing treatment-related morbidity (for lower-risk patients). Here we review advances in the understanding of prognostic factors and their application. We also highlight novel treatment approaches aimed at improving outcomes in childhood ALL.
authors: Department of Pediatric Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. lynda_vrooman@dfci.harvard.edu.|Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA. lynda_vrooman@dfci.harvard.edu.
authors: Lynda M
authors: LM
authors: Vrooman
authors: Department of Pediatric Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.|Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA.
authors: Lewis B
authors: LB
authors: Silverman
mesh_terms: D002648:Child; D003582:Cytogenetics; D006801:Humans; D051740:Ikaros Transcription Factor / Q000172:deficiency / Q000235:genetics; D007167:Immunotherapy; D055118:Medication Adherence; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D033581:Stem Cell Transplantation
chemical_list: C497239:IKZF1 protein, human; D047428:Protein Kinase Inhibitors; D051740:Ikaros Transcription Factor
keywords: Acute lymphoblastic leukemia; Relapse; Treatment